Asana BioSciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Asana BioSciences sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Asana BioSciences: 11 sponsored US clinical trials, none currently recruiting.

Asana BioSciences sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dermatitis Eczema, with 1 trials.

Top-decile sponsor footprint

Asana BioSciences ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

7 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED Phase 1

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
COMPLETED Phase 2

Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema

NCT03728504
COMPLETED Phase 1

Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects

NCT03641573
TERMINATED Phase 2

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

NCT03654755
COMPLETED Phase 2

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

NCT03531957
COMPLETED Phase 1

A Study of ASN007 in Patients With Advanced Solid Tumors

NCT03415126
COMPLETED Phase 1

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

NCT03139981
TERMINATED Phase 1

Study of ASN003 in Subjects With Advanced Solid Tumors

NCT02961283
COMPLETED Phase 1

Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers

NCT02853643
TERMINATED Phase 1

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

NCT02440685
TERMINATED Phase 1

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

NCT02349139

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 3

Therapeutic Areas

Dermatitis Eczema 1
Pruritus 1
Dermatitis, Atopic 1

How the Asana BioSciences early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 7 completed (64%).

Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Dermatitis Eczema (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Asana BioSciences: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Asana BioSciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Asana BioSciencesAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Asana BioSciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Asana BioSciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Asana BioSciences page

11 registered trials is a research-attention snapshot, not an endorsement of Asana BioSciences or any single study.

  • None of Asana BioSciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Dermatitis Eczema is the condition Asana BioSciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dermatitis Eczema trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Asana BioSciences pipeline card: 11 registered trials from official public datasets.Report a data error.